To validate the clinical significance of MFSD4A or EPHA2, we collected samples from 116 patients with NPC from Guilin Medical University Affiliated Hospital diagnosed between November 2012 and March 2013 and conducted immunohistochemical analysis (As for EPHA2, 113 of the 116 patients were included for immunohistochemical analysis, because 3 columns of tissue sections were exhausted). The gene discussed is SLC60A1; the disease is nasopharyngeal carcinoma.